FDA Will Revise Review Order For Generic Drugs Under GIVE Project
This article was originally published in The Pink Sheet Daily
First generic products – those with no blocking patents or exclusivity protections on the reference listed drug – will get expedited review, agency says.
You may also be interested in...
Voluntary collaboration will help FDA develop quality standards for submission of microarray data.
Drug makers need to continue investing in early-stage research to unveil the next $1 billion-plus drug, panelists at the Argyle conference agree.
Phase III data for Affymax/Takeda's anemia drug for chronic kidney failure signals potential regulatory hurdles in non-dialysis use.